Kahn Brothers Kahn Brothers Group
Kahn Brothers Group is a value investment firm founded in the tradition of Benjamin Graham and long associated with the Kahn family of investors. The firm is known for deep-value security analysis, patience, and a multi-decade orientation to intrinsic value. Its filings are followed by classic value investors seeking Graham-and-Dodd style managers still active in public markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$74M |
| 2 |
Citigroup
C
|
+$65.4M |
| 3 |
Merck
MRK
|
+$56.9M |
| 4 |
FLG
Flagstar Bank National Association
FLG
|
+$54.1M |
| 5 |
New York Times
NYT
|
+$53M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.79% |
| 2 | Healthcare | 25% |
| 3 | Communication Services | 9.35% |
| 4 | Energy | 6.74% |
| 5 | Consumer Staples | 6.05% |
Similar funds
Kahn Brothers's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Kahn Brothers, which disclosed 47 positions worth $648M. Its ten largest holdings account for 78% of the portfolio.
Its largest position is Pfizer: 2,678,870 shares worth $71.2M.
By sector, the portfolio is most concentrated in Financials at 34% of assets, followed by Healthcare and Communication Services.
- Kahn Brothers's largest Q2 2013 buy was Pfizer: 2,678,870 shares worth $71.2M.
- Kahn Brothers's ten largest holdings make up 78% of its $648M portfolio in Q2 2013.
- Kahn Brothers disclosed 47 positions in Q2 2013, its first 13F filing on record.
Based on Kahn Brothers Group's 13F filing for Q2 2013, filed 9 Aug 2013.